Oppenheimer initiated coverage on Vaxart Inc. VXRT, an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines. The analyst's bullish view is centered around optimism associated with attractive opportunities for Vaxart's 'differentiated' oral vaccine platform and key programs, such as the norovirus vaccine and COVID-19 vaccine. Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside. ...

VAXART, INC. (VXRT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -400%. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced a loss of $0.14, delivering a surprise of 12.50%. Over the last four quarters, the company has surpassed consensus ...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August 8, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click here Date: Thurs ...

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August 8, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click here Date: Thurs ...

Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Ed Berg - Senior Vice President and General Counsel Steven Lo - Chief Executive Officer Sean Tucker - Founder and Chief Scientific Officer James Cummings - Chief Medical Officer Phil Lee - Chief Financial Officer Conference Call Participants Madison Britt Wynne El-Saadi - B. Riley Securities Aseah Khan - Cantor Fitzgerald Liang Cheng - Jefferies Operator Greetings, and welcome to the Vaxart Business Upda ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such re ...

Exhibit 99.1 Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the ef ect of the disease in infants "We are excited about the potential for our oral pill vaccine technology, not only for the Company but for the benefit of society. We believe the data we have generated to date are compelling and demonstrate our vaccines' potentia ...

Financial Data and Key Metrics Changes - Revenue for 2023 was $7.4 million, a significant increase from $0.1 million in 2022, primarily driven by work performed under a grant from the Bill & Melinda Gates Foundation and non-cash royalty revenue from increased sales of Inavir in Japan [28] - Vaxart ended 2023 with cash, cash equivalents, and investments totaling $39.7 million, excluding approximately $15 million in net proceeds raised in early 2024, with an anticipated cash runway into the fourth quarter of 2024 [28] Business Line Data and Key Metrics Changes - The company made solid progress on its oral vaccine platform, completing two Phase 2 clinical studies for norovirus oral vaccine candidates, establishing proof of concept in challenge studies for both respiratory and gastrointestinal viruses [8][12] - The COVID-19 program received a $9.27 million contract from BARDA to prepare for a 10,000-subject Phase 2b clinical trial, indicating strong governmental support for Vaxart's differentiated approach [17][18] Market Data and Key Metrics Changes - The company believes it has the most advanced norovirus vaccine candidate in clinical development, which is formulated for oral administration and designed for gastrointestinal delivery, addressing a significant economic burden from norovirus [13] Company Strategy and Development Direction - Vaxart is focused on advancing its mucosal vaccine technology, aiming to provide faster, easier, and pain-free vaccination options without the need for cold chain storage or trained medical professionals [9] - The appointment of Steve Lo as the new CEO is expected to elevate the company and create value for shareholders, leveraging his extensive experience in biopharma [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory, highlighting 2023 as a transformational year and emphasizing the need for better vaccines that harness mucosal immunity to combat evolving viruses [11][12] - The company plans to meet with the FDA in Q2 2024 to discuss data on potential correlates of protection and the next steps for its norovirus program [26][27] Other Important Information - The company is preparing to initiate a Phase 2b trial for its COVID-19 vaccine candidate, which may start as early as Q2 2024, and is working to secure additional funding for this study [19][20] Q&A Session Summary Question: Can you talk about the lactating mother study and its potential impact? - The study aims to see antibodies in breast milk that could protect infants, potentially blocking transmission in the community [30][31] Question: What are the economics of the BARDA NextGen funding? - The BARDA contract provides funding for the Phase 2b COVID-19 trial, with potential for additional funds as milestones are met [34][35] Question: How would protection correlates impact the Phase 3 study plan? - Establishing correlates of protection could reduce the number of subjects needed for testing in a Phase 3 study and bridge different age groups [36][37] Question: What are the key considerations for the potential Phase 2 G24 challenge study? - The necessity of the study will be clarified after discussions with the FDA [39] Question: How fast could a challenge study be initiated? - The timeline depends on FDA guidance, but preparations are in place to move quickly if required [44]

FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35285 Vaxart, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 59-1212264 | | | ...

Exhibit 99.1 Vaxart Provides Business Update and Reports Full Year 2023 Financial Results Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study in lactating mothers expected in mid-2024 Steven Lo appointed President, Chief Executive Of icer and Board Member Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 14, 2024 — Vaxart, Inc. (Nasdaq: VXRT) ...